Growing evidence suggests the outcome of Mycobacterium tuberculosis (Mtb) infection is 17 established rapidly after exposure, but how the current tuberculosis vaccine, BCG, impacts early 18 immunity is poorly understood. Here we found that murine BCG immunization promotes a 19 dramatic shift in infected cell types. While alveolar macrophages (AM) are the major infected 20 cell for the first two weeks in unimmunized animals, BCG promotes the accelerated recruitment 21 and infection of lung infiltrating phagocytes. Interestingly, this shift is dependent on CD4 T 22 cells, yet does not require intrinsic recognition of antigen presented by infected AM. Mtb-23 specific T cells are first activated in lung regions devoid of infected cells, and these events 24 precede vaccine-induced reduction of the bacterial burden, which occurs only after the co-25
Introduction 28
Bacillus Calmette-Guerin (BCG), the current tuberculosis (TB) vaccine, is effective at 29 preventing disseminated disease in infants and young children (1). However, in most settings it 30 provides little or no protection against adult pulmonary TB, the transmissible form of disease (2). 31
Thus, despite widespread BCG immunization for nearly a century, Mycobacterium tuberculosis 32 (Mtb) kills over 1.5 million people every year, more than any other single infectious agent (3). A 33 better TB vaccine is urgently needed, but attaining this goal has been surprisingly difficult (4) . 34
Furthermore, because BCG reduces childhood mortality, a new vaccine will likely be added to a 35 regimen that includes BCG, rather than replace it (5). To develop a strategy that builds upon 36 BCG-mediated protection, we must first understand how BCG shapes immunity to Mtb, 37 especially during early stages of infection when protective immunity is established. 38
In mice, pulmonary Mtb burdens are equivalent between BCG-immunized and control mice until 39 two weeks after infection (6) . The failure of BCG to impact the Mtb burden during the first two 40 weeks of infection has been attributed to the delayed arrival of T cells in the lung (7) . However, 41 BCG-specific T cells have been shown to be present in the lungs (8) of immunized mice even 42 prior to Mtb challenge, indicating that impaired T cell recruitment cannot fully account for the 43 inability of BCG to induce early protection. 44
45
In this study, we utilized the mouse model to investigate the impact of BCG on the early immune 46 response to Mtb infection. Our findings reveal unexpected roles for CD4 T cells in: 1) 47 accelerating the translocation of Mtb-infected alveolar macrophages (AM) into the lung 48 interstitium; 2) recruiting monocyte-derived macrophages; and 3) promoting the early transfer of 49
Mtb from AM to other phagocytes. 50
Materials and Methods 51
Mice 52 C57BL/6 and MHCII -/mice were purchased from Jackson Laboratories (Bar Harbor, ME). All 53 mice were housed in specific pathogen-free conditions at Seattle Children's Research Institute 54 (SCRI). Experiments were performed in compliance with the SCRI Animal Care and Use 55
Committee. Both male and female mice between the ages of 8-12 weeks were used. 56
57

BCG immunization 58
BCG-Pasteur was cultured in Middlebrook 7H9 broth at 37°C to an OD of 0.2-0.5. Bacteria was 59 diluted in PBS and 10 6 CFU in 200ul was injected subcutaneously. After immunization, mice 60
were rested for 8 weeks prior to Mtb infection. 61
62
Aerosol Infections 63
Infections were performed with wildtype H37Rv Mtb or H37Rv transformed with an mCherry 64 reporter plasmid (9). Mice were enclosed in a Glas-Col aerosol infection chamber and 50-100 65 CFU were deposited directly into the lungs. 66 67
Intratracheal and intravenous labeling 68
For intratracheal labeling, 30min prior to sacrifice, mice were anesthetized with 25% isoflurane 69 in propylene glycol (Fisher Scientific) and 0.25ug of CD45.2 PE-Cy7 in 50ul of PBS was 70 pipetted into the airway. For intravenous (i.v.) labeling, mice were anesthetized as above and 71 infused with CD45.2 PE 10 min prior to sacrifice. 72
73
Lung cell isolation and antibody staining 74
Mouse lungs were homogenized in HEPES buffer with Liberase Blendzyme 3 (70ug/ml; Roche) 75 and DNaseI (30ug/ml; Sigma-Aldrich) using a gentleMacs dissociator (Miltenyi Biotec). Lungs 76 were incubated at 37°C for 30 min and then further homogenized with the gentleMacs. Cells 77 were filtered through a 70um cell strainer and resuspended in RBC lysis buffer (Thermo) prior to 78 a PBS wash. Cells were next incubated with 50ul Zombie Aqua viability dye (BioLegend) for 79 10min at room temperature. Viability dye was quenched with 100ul of antibody cocktail in 50% 80 FACS buffer (PBS containing 2.5% FBS and 0.1% NaN3)/50% Fc block buffer. Staining was 81 performed for 20min at 4°C. Cells were washed with FACS buffer and fixed with 2% 82 paraformaldehyde for 1hr prior to analysis on an LSRII flow cytometer (BD Biosciences). When 83 stain sets contained tetramers, staining was performed for 1hr at room temperature. Ag85B and 84 TB10.4 tetramers were obtained from the NIH Tetramer Core Facility. 85
86
Imaging 87
Mice were infected with H37Rv Mtb-mCherry and sacrificed at D10 and D14. Lungs were 88 excised and submerged in BD Cytofix fixative solution diluted 1:3 with PBS for 24hr at 4°C. 89
Lungs were washed 2x in PBS and dehydrated in 30% sucrose for 24hr prior to OCT embedding 90 and rapid freezing in a methylbutane-dry ice slurry. 20um sections were stained overnight at 91 room temperature and coverslipped with Fluoromount G mounting media (Southern Biotec). 92
Images were acquired on a Leica SP8X confocal microscope, compensated for fluorophore 93 spillover using LAS X (Leica), and analyzed with Imaris (Bitplane) and FlowJo (10). 94
T cell depletion 96
Mice were intraperitoneally injected with 400ug anti-CD4 GK1.5 or anti-CD8 2.43 (BioXcell) in 97 PBS at D-1, D4, and D10 relative to infection. 98
Bone marrow chimeras 99 WT CD45.1/2 F1 mice were irradiated with 1000 rads and reconstituted with a 1:1 mixture of 100 CD3-depleted (Miltenyi Biotec) CD45.1 B6.SJL:CD45.2 MHCII -/bone marrow. At D56 post-101 reconstitution, mice were immunized with BCG. 102 103 Th1 polarization and adoptive transfers 104 CD4 T cells from ESAT-6-specific (C7) (11) CD90.1 + and OVA-specific (OTII) CD45.1 + TCR 105 transgenic mice were negatively enriched from spleens using EasySep magnetic microbeads 106 (STEMCELL). T cells were Th1 polarized as follows: 1.6 × 10 6 transgenic T cells were cultured 107 with 8.3 × 10 6 irradiated CD3splenocytes. 5 μg/ml of ESAT-6 or OVA peptide, 10 ng/ml IL-12, 108 and 10 μg/ml of anti-IL-4 antibody (R&D Systems) were added at D0. At D3, cells were split 109 1:2, and 10 ng/ml IL-12 was added (R&D Systems). On D5, Th1 cells were i.v. injected into B6 110 CD45.2 + mice infected with Mtb 35 days prior. 111
Results and Discussion 112
BCG vaccination promotes Mtb egress from AM early in infection. 113
To understand the effects of BCG immunization on early Mtb infection, we examined the 114 pulmonary Mtb burdens in BCG-immunized and control mice. Consistent with prior reports (6, 115 7), lung burdens rose similarly in both groups through two weeks ( Fig. 1A) . At D15, the Mtb 116 burden in the immunized group began to diverge and was reduced by one log by D21. These 117 findings are consistent with the idea that BCG-induced immunity is not initiated until the third 118
week of Mtb infection. 119
120
We recently found that Mtb first infects AM before disseminating to other cells including 121 neutrophils (PMN) and monocyte-derived macrophages (MDM) (12). As tissue-resident and 122 recruited phagocytes have been shown to differ in their capacity to curb Mtb replication (13, 14) , 123
we next asked whether immunization alters the proportions of cell types that harbor infection. 124
Consistent with the similar Mtb burdens at D14, the numbers of cells harboring fluorescent Mtb 125 (Mtb-mCherry) were also similar in each group (Fig. 1B) . Surprisingly, even at this early phase, 126
we observed a dramatic shift in the composition of infected cells. At D14, the proportion of Mtb-127 infected AM was significantly reduced in immunized animals compared to controls, with a 128 corresponding increase in infected PMN and MDM (Fig. 1C-D) . We confirmed these findings 129 using confocal microscopy and quantitative histocytometry (10), wherein most Mtb was within 130
SiglecF + AM at D14 in controls but within CD11b + SiglecFcells (primarily PMN and MDM) in 131 immunized mice ( Fig. 1E-F ). As Mtb dissemination to PMN and MDM requires translocation of 132 infected AM to the lung interstitium (12), we next assessed whether this translocation was 133 accelerated in immunized mice. Indeed, intratracheal antibody administration, which specifically 134 labels alveolar-localized cells (12), revealed significantly increased interstitial localization (label-135 negative) of infected AM in immunized mice at D14 (Fig. 1G ). Finally, immunization 136 significantly enhanced MDM recruitment to the lung at D14 (Fig. 1H) , which was not observed 137 at earlier time points or in Mtb-naïve mice (Supplemental Fig. 1A ), suggesting that the 138 antigen-specific CD4 (Ag85B) and CD8 (TB10.4) T cells could be identified in lung cell 148 suspensions of immunized mice ( Fig. 2A-C) . Although ~25% of the Ag85B-specific cells were 149 located in the lung parenchyma (as evidenced by their failure to stain with i.v. CD45 antibody), 150 virtually all of the TB10.4-specific cells resided in the vasculature (Fig. 2D ). Following 151 infection, immunized mice had significantly more Ag85B-specific and TB10.4-specific cells in 152 the lung parenchyma than controls as early as D10; by D14 they contained >5-fold more ( Fig.  153 2B-C). Thus, BCG induces a small population of lung-resident Mtb-specific CD4 T cells prior to 154 infection. After infection, BCG accelerates the pulmonary recruitment of both CD4 and CD8 155
Mtb-specific T cells, even before impacting the Mtb burden. 156
CD4 T cells are required for the accelerated transfer of Mtb from AM to recruited 158
phagocytes. 159
Given the presence of lung-resident Mtb-specific T cells in immunized mice prior to infection, 160 we next determined whether T cells play a role in the accelerated transfer of Mtb from AM to 161 other myeloid cells. CD4 or CD8 T cells were depleted from immunized mice beginning 1 day 162 prior to Mtb-mCherry infection and lung cells were assessed at D14 (Supplemental Fig. 1B-C) . 163
In the absence of CD4 T cells, the accelerated transfer of Mtb from AM to PMN and MDM was 164 partially reversed, whereas CD8 T cell depletion had no effect (Fig. 3A) . Interestingly, the 165 accelerated MDM recruitment (Fig. 1H ) was also abolished by CD4 depletion (Fig. 3B ). We next 166 investigated whether direct recognition of Mtb-infected cells by CD4 T cells was required for the 167 early dissemination out of the AM niche and whether MHCII -/-AM, which cannot present 168 antigen to CD4 T cells, would retain Mtb longer than WT AM. WT:MHCII -/mixed bone 169 marrow chimeras were generated, BCG immunized, and infected with Mtb-mCherry. At D14, 170 BCG induced the accelerated transfer of Mtb from AM to other myeloid cells irrespective of 171 intrinsic MHCII expression ( Fig. 3C ). Taken together, BCG-induced CD4 T cells promote the 172 early transfer of Mtb from AM to other myeloid cells in a process that does not require direct 173 cognate interactions between T cells and Mtb-infected AM. Our finding that CD4 T cells 174 promote MDM recruitment to the lung, thereby providing new bacterial targets, may help 175 explain the increased proportion of infected MDM in immunized animals. This recruitment 176 likely relates to T cell production of cytokines, such as IFN-gamma and TNF, which are known 177 to trigger the release of chemokines that act on MDM, i.e., CCL2 and CXCL10 (15) . 178
179
BCG-induced CD4 T cells are initially activated distal to the site of Mtb infection. 180
We next investigated the site of CD4 T cell activation during early Mtb infection using phospho-181 S6 (pS6) as a marker of TCR signaling, which is rapidly induced by TCR engagement, peaking 182 at 4 h and resolving within 24 h (16). To confirm that pS6 expression by T cells is TCR-183 dependent in the context of Mtb-infected lungs, we demonstrated that pS6 was robustly 184 expressed by adoptively transferred TCR transgenic Mtb-specific (ESAT-6; C7) CD4 T cells 185 compared to irrelevant TCR transgenic T cells (OVA-specific) (Supplemental Fig. 2A ). We next 186 performed quantitative histocytometry to assess the intrapulmonary location of pS6 expression 187 by CD4 T cells. At D10, there were significantly more pS6 + CD4 T cells in the lungs of 188 immunized mice compared to controls ( Fig. 4A-B, Supplemental Fig. 2F) . Surprisingly, few of 189 these cells were located near infected cells (Fig. 4A, 4D finally co-localize with cells harboring Mtb, as evidenced by the identification of many pS6 + T 203 cells at sites of infection compared to controls ( Fig. 4C-D) . This is consistent with the finding 204 that optimal immunity against Mtb requires direct interactions between antigen-specific CD4 T 205
cells and Mtb-infected cells (21). Why do T cells and Mtb-infected cells not co-localize earlier? 206
The AM is the first cell type to become infected and remains the primary infected cell type for at 207 least a week (12). During this time, the immune system appears largely unaware of the looming 208 
